<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032248</url>
  </required_header>
  <id_info>
    <org_study_id>behcet</org_study_id>
    <nct_id>NCT05032248</nct_id>
  </id_info>
  <brief_title>Uses of Tacrolimus in Behcet Disease</brief_title>
  <official_title>Uses of Tacrolimus in Treatment of Oral Ulcers in Behcet Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: oral ulceration is the earliest and commonest manifestation of Behcet's disease&#xD;
      (BD). Minor aphthous like ulcers (&lt;10 mm in diameter) are the most common type (85%); major&#xD;
      or herpetiform ulcers are less frequent. It is occurred about in Egypt; 3.6/100,000 % and&#xD;
      high recurrence rate with traditional treatment. Colchicine is the first line of treatment in&#xD;
      mucocutaneous manifestation of BD through its anti-inflammatory effect. Tacrolimus oral gel&#xD;
      is safe and effective in treating aphthous ulcers in many diseases. Objectives: to compare&#xD;
      the clinical efficacy of topical tacrolimus versus oral colchicine upon disease activity,&#xD;
      pain and ulcer severity in oral ulcer associated with BD. Study design: A randomized double&#xD;
      -blinded trial.&#xD;
&#xD;
      Setting: Rheumatology clinic, Assiut University Hospital and Faculty of Dental Medicine,&#xD;
      AlAzhar University, Assiut branch outpatient's clinic. Methods: 40 BD participants (&gt; 3&#xD;
      months taken traditional treatment with persistent active oral ulceration). They have been&#xD;
      equally randomized into either group I (Colchicine and topically applied Tacrolimus), or&#xD;
      group II (Colchicine only). Measurements: Behcet's Disease Current Activity Form (BDCAF),&#xD;
      Ulcer Severity Score (USS) and visual analog scale (VAS) pre-injection, then re-evaluated&#xD;
      postinjection at four-time points (15 days, 1st, 2nd and 3rd months) and Determination of&#xD;
      Natural Killer (NK) cells number in salival wash before treatment (at base line) and after&#xD;
      the treatment (after 3 months)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: oral ulceration is the earliest and commonest manifestation of Behcet's disease&#xD;
      (BD). Minor aphthous like ulcers (&lt;10 mm in diameter) are the most common type (85%); major&#xD;
      or herpetiform ulcers are less frequent. It is occurred about in Egypt; 3.6/100,000 % and&#xD;
      high recurrence rate with traditional treatment. Colchicine is the first line of treatment in&#xD;
      mucocutaneous manifestation of BD through its anti-inflammatory effect. Tacrolimus oral gel&#xD;
      is safe and effective in treating aphthous ulcers in many diseases. Objectives: to compare&#xD;
      the clinical efficacy of topical tacrolimus versus oral colchicine upon disease activity,&#xD;
      pain and ulcer severity in oral ulcer associated with BD. Study design: A randomized double&#xD;
      -blinded trial.&#xD;
&#xD;
      Setting: Rheumatology clinic, Assiut University Hospital and Faculty of Dental Medicine,&#xD;
      AlAzhar University, Assiut branch outpatient's clinic. Methods: 40 BD participants (&gt; 3&#xD;
      months taken traditional treatment with persistent active oral ulceration). They have been&#xD;
      equally randomized into either group I (Colchicine and topically applied Tacrolimus), or&#xD;
      group II (Colchicine only). Measurements: Behcet's Disease Current Activity Form (BDCAF),&#xD;
      Ulcer Severity Score (USS) and visual analog scale (VAS) pre-injection, then re-evaluated&#xD;
      postinjection at four-time points (15 days, 1st, 2nd and 3rd months) and Determination of&#xD;
      Natural Killer (NK) cells number in salival wash before treatment (at base line) and after&#xD;
      the treatment (after 3 months)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ulcer Severity Score (USS)</measure>
    <time_frame>3 months</time_frame>
    <description>Ulcer Severity Score (USS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Oral Ulcer</condition>
  <condition>Behcet Syndrome</condition>
  <arm_group>
    <arm_group_label>tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group I (Colchicine and topically applied Tacrolimus),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group II (Colchicine and topically applied Placebo),</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus ointment</intervention_name>
    <description>oral gel</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  active oral ulcers for Behcet's Disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who received biological therapy comorbid systemic diseases allergy to&#xD;
             Tarcolimus drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut governorate</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Manal Hassanien</investigator_full_name>
    <investigator_title>assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Oral Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

